Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University Medical Centre Groningen Netherlands Heart Foundation |
---|---|
Information provided by: | University Medical Centre Groningen |
ClinicalTrials.gov Identifier: | NCT00392431 |
Our hypothesis is that episodic amiodarone treatment (i.e. amiodarone treatment 1 month prior until 1 month after cardioversion) is associated with a lower morbidity and a higher quality of life compared to continuous prophylactic amiodarone treatment while atrial fibrillation is still effectively suppressed. The latter means that at the end of the study permanent atrial fibrillation is prevented in comparable percentage of patients (70%) in both treatment strategies. However, this will be accomplished at the cost of a higher number of electrical cardioversions (2-3) in the episodic treatment group compared to the continuous treatment group.
Condition | Intervention |
---|---|
Persistant Atrial Fibrillation |
Drug: amiodarone |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Continuous Versus Episodic Prophylactic Treatment With Oral Amiodarone for the Prevention of Permanent Atrial Fibrillation: a Randomized Study on Morbidity and Quality of Life |
Estimated Enrollment: | 220 |
Study Start Date: | January 2003 |
Study Completion Date: | March 2007 |
Primary objective
To determine differences in adverse event rates between patients with persistent atrial fibrillation who are randomized to episodic amiodarone treatment (EAT) strategy and patients who are randomized to continuous amiodarone treatment (CAT) strategy, while atrial fibrillation is still effectively suppressed.
Adverse events can be related to:
Secondary objective
To determine differences in quality of life between patients with persistent atrial fibrillation who are randomized to the EAT strategy and patients who are randomized to the CAT strategy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Netherlands | |
University Medical Center Groningen | |
Groningen, Netherlands, 9700RB |
Principal Investigator: | Isabelle C Van Gelder, MD | University Medical Centre Groningen |
Study ID Numbers: | 2000B133 |
Study First Received: | October 25, 2006 |
Last Updated: | March 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00392431 History of Changes |
Health Authority: | European Union: European Medicines Agency |
Vasodilator Agents Heart Diseases Quality of Life Cardiovascular Agents |
Anti-Arrhythmia Agents Atrial Fibrillation Amiodarone Arrhythmias, Cardiac |
Vasodilator Agents Heart Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Cardiovascular Agents Amiodarone Pharmacologic Actions |
Pathologic Processes Therapeutic Uses Cardiovascular Diseases Atrial Fibrillation Anti-Arrhythmia Agents Arrhythmias, Cardiac |